Foghorn Therapeutics and Eli Lilly have decided to discontinue the clinical development of FHD-909 and the Selective SMARCA2 degrader program, effectively ending their collaboration. This decision, based on a review of Phase 1 clinical data for FHD-909, will likely have a significant negative impact on Foghorn's stock due to the loss of a key partnership and pipeline assets.
Foghorn Therapeutics and Eli Lilly have announced the termination of their collaboration, ceasing further development of the FHD-909 and Selective SMARCA2 degrader programs. This decision stems from a review of Phase 1 clinical data for FHD-909, indicating that the program will not advance to the expansion phase. For Foghorn, this is a major setback as it loses a significant partnership and two pipeline assets, forcing it to re-prioritize its proprietary portfolio. While a negative for Foghorn, the impact on Lilly is likely minimal given its vast and diversified pipeline. Short-term, FHTX shares are expected to face significant downward pressure, while long-term, Foghorn's future now hinges entirely on its remaining proprietary programs. Traders should note the immediate negative catalyst for FHTX and consider the implications for its cash runway and future development strategy.